ChemicalBook
Chinese Japanese Germany Korea

LCZ696

Drugs for heart failure bioactivity In vivo studies
LCZ696
LCZ696 structure
CAS No.
936623-90-4
Chemical Name:
LCZ696
Synonyms
LZC696;Entresto;LCZ696 Entresto;LCZ696 interMediate;LCZ696 (936623-90-4);Valsartan/sacubitril;Valsartan/Sacubitril (1:1);lcz696/Valsartan/sacubitril;Valsartan-sacubitril(LCZ696);Sacubitril-Valsartan complex
CBNumber:
CB72715242
Molecular Formula:
C48H58N6O8
Formula Weight:
847.00952
MOL File:
936623-90-4.mol

LCZ696 Properties

SAFETY

LCZ696 price More Price(2)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 23425 LCZ696 ≥98% (1:1 ratio of Valsartan and AHU377) 936623-90-4 1mg $39 2018-11-19 Buy
Cayman Chemical 23425 LCZ696 ≥98% (1:1 ratio of Valsartan and AHU377) 936623-90-4 5mg $166 2018-11-19 Buy

LCZ696 Chemical Properties,Uses,Production

Drugs for heart failure

LCZ696 a drug developed by Novartis Pharmaceutical of the United States for the treatment of heart failure. Heart failure is a life-threatening disease. The patient's heart cannot pump enough blood to supply the body, and appear the symptoms of dyspnea, fatigue and fluid retention slowly, then gradually increased, significantly affect the quality of life.
LCZ696 is a dual-acting angiotensin-receptor enkephalinase inhibitor that has a unique mechanism that is thought to reduce the strain of failing hearts. LCZ696 can enhance the body's natural defense against heart failure, as well as increase the level of natriuretic peptides and other endogenous vasoactive peptides, and inhibit the renin-angiotensin-aldosterone system (RAAS). LCZ696 has combined with Novartis's Hypertension Medication (Diovan, generic name: valsartan) and the experimental drug AHU-377. AHU377 blocks the mechanism of the two peptides responsible for lowering blood pressure. Diovan improves vasodilatation and stimulates the body to excrete sodium and water.
The safety threshold of cardiovascular drugs is extremely high, and LCZ696 even shows a higher safety than conventional drugs. Previously, Novartis vigorously develop the cardiovascular drug— serelaxi, while because of security issues, both the FDA and the European Union did not grant this drug. This is undoubtedly a heavy blow to Novartis. However, the success of LCZ696 will pay back Novartis a big era in the cardiovascular field.。
In August 2014, Novartis announced significant results as a landmark of PARADIGM-HF trial. LCZ696 was significantly superior to the ACE inhibitor Enalapril at several key end points, including a significant reduction in cardiovascular death risk or heart failure hospitalization rate. These latest analyzes were first disclosed at the American Heart Association Scientific Conference in 2014 and published in Circulation at the same time.
On November 30, 2014, the European Medicines Agency (EMP) Committee for Medicinal Products for Human Use (CHMP) has granted LCZ696 an accelerated eligibility, so it became the first cardiovascular drug to qualify for accelerated evaluation in the history of EU drug regulation. Prior to this, the EU's Accelerated Assessment of Qualifications was never granted to the cardiovascular field.
LCZ696 is an experimental drug developed for the treatment of patients with Heart Failure with reduced Ejection Fraction (HFrEF). Accreditation of Accelerated Evaluation by CHMP means that the review time of LCZ696 will be shortened by 60 days in official EU. Novartis is expected to submit LCZ696 application approval (MAA) in the European Union at the beginning of 2015. The MAA submission will be based on data from the landmark Phase III PARADIGM-HF study, which is the largest study of heart failure patients conducted in the history. The data show that the efficacy and safety of LCZ696 is beyond the clinical standard drug enalapril (enalapril), including significantly reduced cardiovascular death or heart failure hospitalization risk
The industry believes that LCZ696's outstanding performance, make it became one of the most important progress over the past 10 years in the field of cardiology. At the same time, in the next few years, there will be no drug to compete with the LCZ696 in the cardiovascular field. Some analysts predict that the LCZ696 sales peaked at $ 8 billion; while Deutsche Bank analysts expect the drug to peak at $ 6 billion, given LCZ696's superior performance in reducing cardiovascular risk. Although the data are slightly different, but there is no doubt that, LCZ696 will become a super star for Novartis. In addition to bring rolling financial resources, it will lead the cardiovascular treatment step into a new era.
In February 2015, Novartis Pharma Test Drug LCZ696 was given priority review by the US Food and Drug Administration (FDA) for the treatment of Heart Failure with reduced Ejection Fraction (HFrEF). Novartis added that the drug's overall review time will be reduced by 8 months, the FDA may make its approval decision in August.
Novartis said its listing application in US was based on a 3-phase PARADIGM-HF study, which showed a significant reduction in cardiovascular mortality and heart failure hospitalization compared with the ACE inhibitor Enalapril.
This information is compiled and edited by Nan, Xiao Nan from ChemicalBook.

bioactivity

LCZ696, composed of valsartan and sacubitril in a 1: 1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for the treatment of hypertension and heart failure.

In vivo studies

In a double transgenic, overexpressed human renin, angiotensinogen and plasma atrial natriuretic peptide immunoreactivity rat, LCZ696 (60 mg/kg p.o.) induced a persistent decrease and dose-dependence in mean arterial pressure (MAP) and , and stimulated dose-dependent rapid increase of ANP immunoreactivity in plasma. LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction by reducing myocardial fibrosis and cardiac hypertrophy in a rat myocardial infarction (MI) model.

LCZ696 Preparation Products And Raw materials

Raw materials

Preparation Products


LCZ696 Suppliers

Global( 175)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1530 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22043 58
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 wgp@nanjing-pharmaceutical.com CHINA 117 55
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37122233
+86-21-37127788 Candy@bj-chem.com CHINA 500 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20786 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 sales@fine-chemtech.com CHINA 894 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 16534 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 956 58
Shenzhen Nexconn Pharmatechs Ltd
15013857715
admin@nexconn.com CHINA 2519 58
Jinan Shengqi pharmaceutical Co,Ltd
86+15552594168
christine@shengqipharm.com CHINA 339 58

View Lastest Price from LCZ696 manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-21 LCZ696
936623-90-4
US $7.00 / KG 1KG 99% 1000KG career henan chemical co
2018-08-08 LCZ696
936623-90-4
US $1.00 / KG 1KG 99% 100kg career henan chemical co
2018-07-19 LCZ696 (936623-90-4)
936623-90-4
US $10.00-10.00 / G 10UG 99% 1000kg/month Hebei Chisure Biotechnology Co., Ltd.

936623-90-4(LCZ696)Related Search:


  • 3-(1-Biphenyl-4-ylMethyl-3-ethoxycarbonyl-1-butylcarbaMoyl)propionate-3'-Methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylMethyl)aMino)butyrate
  • Valsartan/sacubitril
  • LCZ696 interMediate
  • N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2)
  • Valsartan-sacubitril(LCZ696)
  • sodium (S)-5-(4'-((N-(1-carboxylato-2-methylpropyl)pentanamido)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-1-ide 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate
  • LCZ696 (936623-90-4)
  • Valsartan/Sacubitril (1:1)
  • Entresto,Valsartan/sacubitril
  • Entresto
  • LZC696
  • [(C24H29N5O3).(C24H29NO5).2.5(H2O).3Na]
  • Sacubitril Valsartan (LCZ696)
  • 936623-90-4
  • 2C24H29N5O32C24H29NO55H2O6Na
  • C24H29N5O3C24H29NO552H2O3Na
  • C49H60N6O8
  • Inhibitors
  • Cardiovascular Series
  • LCZ696 Entresto
  • 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate
  • Sacubitril mixture with Valsartan
  • Cocrystal of Sacubitril and Valsartan
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)hexanamido)-3-methylbutanoic acid
  • lcz696/Valsartan/sacubitril
  • Sacubitril-Valsartan complex
Copyright 2017 © ChemicalBook. All rights reserved